Gilead Sciences, Inc.
13F holdings for Q2 2026 · FOSTER CITY, CA · filed August 3, 2026
Gilead Sciences, Inc. reported $1.1B in 13F securities across 4 holdings for Q2 2026, in a Form 13F filed August 3, 2026. The largest positions were RCUS (84.3%), ASMB (11.9%), KYTX (3.2%). Reported value fell 28.9% from the quarter before. It opened 0 new positions, added to 1, trimmed 0 and sold out of 1.
- 13F value Q2 2026
- $1.1B
- Holdings
- 4
- Change vs prior quarter
- -28.9%
- Rank by 13F value
- #2,313
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Top holdings
| Stock | Value | Weight | Shares | Change in shares | Move |
|---|---|---|---|---|---|
| RCUS Arcus Biosciences Inc. | $969M | 84.3% | 31,424,760 | 0% | Unchanged |
| ASMB Assembly Biosciences Inc. | $137M | 11.9% | 4,977,089 | +10.5% | Added |
| KYTX Kyverna Therapeutics Inc. | $36.8M | 3.2% | 4,126,119 | 0% | Unchanged |
| Xilio Therapeutics Inc. | $6.2M | 0.5% | 650,389 | 0% | Unchanged |
Share positions only, at the value reported for the end of Q2 2026. Weight is the share of $1.1B in share positions; options and bonds count in the 13F value but not here.
Biggest buys in Q2 2026
- ASMB Assembly Biosciences Inc. Added+$13.0M
Biggest sells in Q2 2026
- Arcellx Inc Sold out-$772M
The change in shares since Q1 2026, adjusted for stock splits and priced at the Q2 2026 value per share. 0 new, 1 added, 0 trimmed, 1 sold out.
Sector mix
- Health Care99.5%
- Not listed with us0.5%
13F value by quarter
Schedule 13D and 13G filings by Gilead Sciences, Inc.
Stakes above 5% of a company, filed within days rather than once a quarter.
- 2026-11-06ASPE SCHEDULE 13G filed by Aspen Neuroscience Inc.Schedule 13G
- 2026-02-23ACLX SCHEDULE 13D filed by Arcellx Inc.Schedule 13D
Questions about Gilead Sciences, Inc.
- What does Gilead Sciences, Inc. own?
- In its Form 13F for Q2 2026, Gilead Sciences, Inc. reported 4 holdings worth $1.1B. The five largest were RCUS, ASMB, KYTX, Xilio Therapeutics Inc..
- What did Gilead Sciences, Inc. buy and sell in Q2 2026?
- Gilead Sciences, Inc. opened 0 new positions, added to 1, trimmed 0 and sold out of 1 compared with the quarter before.
- When did Gilead Sciences, Inc. file its latest 13F?
- Form 13F is due 45 days after each quarter ends. The Q2 2026 report was due August 14, 2026 and was filed August 3, 2026.
From Form 13F filed by Gilead Sciences, Inc. (SEC CIK 0000882095) for the quarter ended June 30, 2026, via the SEC's Form 13F data sets. Amendments that restate a report replace it; amendments that add holdings are included. View on SEC EDGAR · All funds